Journal article

Cross-resistance to human cationic antimicrobial peptides and to polymyxins mediated by the plasmid-encoded MCR-1?

  • Dobias, Jan Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland
  • Poirel, Laurent Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland
  • Nordmann, Patrice Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland - Insitute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland
    23.03.2017
Published in:
  • Clinical Microbiology and Infection. - 2017
English To evaluate whether acquired resistance to cationic antimicrobial peptides (CAMP) group molecules, being normal components of the human immune system, may select co-resistance to antibiotic peptides such as polymyxins, considering they share the same mechanism of action. We aimed to evaluate strains producing the recently identified plasmid-encoded polymyxin resistance determinant MCR-1, which is a phosphoethanolamine transferase that modifies the lipopolysaccharide structure of Gram-negative bacteria.Methods: In-vitro susceptibility studies using human CAMPs, namely cathelicidin LL-37, α-defensin 5 (HD5) and β-defensin 3 (HDB3), towards MCR-1-producing and colistin-resistant Escherichia coli or Klebsiella pneumoniae were performed.Results: Cross-resistance to CAMPs and colistin mediated by MCR-1 or chromosomal mechanisms was neither observed in E. coli nor in K. pneumoniae.Conclusion: Therefore, the future therapeutic development of human CAMPs may likely not be impeded by the spread of MCR-1 plasmid-mediated resistance to polymyxins, at least in E. coli.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/305495
Statistics

Document views: 10 File downloads:
  • nor_crh.pdf: 1